Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$1.79 USD
+0.09 (5.29%)
Updated Aug 5, 2025 03:57 PM ET
After-Market: $1.79 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Aprea Therapeutics, Inc. has a market cap of $9.40M, which represents its share price of $1.70 multiplied by its outstanding shares number of 5.53M. As a small-cap company, APRE's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
APRE 1.79 +0.09(5.29%)
Will APRE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APRE
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates
APRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates
XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates
Other News for APRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
Aprea Therapeutics (APRE) Reports Promising Data on APR-1051 for HPV+ Cancer | APRE Stock News
Aprea Therapeutics announces new preclinical data, update on APR-1051
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for ...
Aprea Therapeutics announces new preclinical data, update on APR-1051